Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the market has dropped 4.4%, yet in the last year, it is up 19%, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust opportunities in the United States market.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.39%	43.54%	★★★★★★
Super Micro Computer	20.49%	27.13%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Ardelyx	27.44%	65.92%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Ascendis Pharma	39.71%	68.43%	★★★★★★
Travere Therapeutics	26.72%	68.41%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Heron Therapeutics (NasdaqCM:HRTX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Heron Therapeutics, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing therapies that improve medical care, with a market cap of $273 million.

Operations: Heron Therapeutics focuses on developing and commercializing therapeutic products, generating $136.36 million in revenue from its drug delivery systems segment. The company aims to enhance patient care through innovative medical solutions.

Heron Therapeutics has made significant strides in reducing its net loss from $42.06 million to $9.24 million year-over-year, reflecting a 78% improvement. The company's R&D expenses have been pivotal, with a substantial investment of $26.59 million aimed at advancing their pain management solutions like ZYNRELEF®. This product's inclusion in the proposed 2025 Non-Opioid Policy for Pain Relief under Medicare highlights its potential impact on opioid alternatives in surgical settings, potentially driving future revenue growth by 17.4%.

• Navigate through the intricacies of Heron Therapeutics with our comprehensive health report here.

• Gain insights into Heron Therapeutics' historical performance by reviewing our past performance report.

Viant Technology (NasdaqGS:DSP)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Viant Technology Inc. operates as an advertising technology company with a market cap of $636.41 million.

Operations: The company generates revenue primarily through its Internet Information Providers segment, which reported $243.25 million.

Viant Technology has shown notable growth, with second-quarter sales increasing to $65.87 million from $57.22 million a year ago and net income reaching $0.055 million compared to a net loss of $1.06 million previously. The company's R&D expenses, which amounted to 11.6% of revenue, underscore its commitment to innovation, particularly in AI-driven advertising solutions like the upgraded AI Bid Optimizer that improved performance by 100%. Additionally, Viant's recent share repurchase program saw the company buy back 818,138 shares for $8 million between April and August 2024, representing nearly 5% of outstanding shares. Viant's strategic focus on cookieless advertising technology is gaining traction as evidenced by a successful test with Havas Media Network achieving a remarkable 93% unique reach across premium publishers without traditional cookies. This shift addresses growing privacy concerns and positions Viant well in the evolving digital ad landscape where identity resolution is crucial for advertisers seeking scalable solutions post-cookie era.

• Click here to discover the nuances of Viant Technology with our detailed analytical health report.

• Assess Viant Technology's past performance with our detailed historical performance reports.

MeiraGTx Holdings (NasdaqGS:MGTX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MeiraGTx Holdings plc is a clinical-stage gene therapy company dedicated to developing treatments for patients with serious diseases, with a market cap of $300.31 million.

Operations: MeiraGTx Holdings plc generates revenue primarily from its biotechnology segment, specifically startups, amounting to $8.12 million. The company focuses on developing gene therapy treatments for serious diseases.

MeiraGTx Holdings is seeing significant revenue growth, forecasted at 40.5% annually, outpacing the US market's 8.5%. Despite a current unprofitable status with a net loss of $48.62 million in Q2 2024, R&D expenses underscore their commitment to innovation in gene therapy and other biotech advancements. The recent $50 million follow-on equity offering highlights investor confidence and provides capital for further research, potentially accelerating their path to profitability within three years as projected earnings grow at 7.8% annually.

• Click here and access our complete health analysis report to understand the dynamics of MeiraGTx Holdings.

• Examine MeiraGTx Holdings' past performance report to understand how it has performed in the past.

Key Takeaways

• Navigate through the entire inventory of 249 US High Growth Tech and AI Stocks here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com